SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026)
SELLAS Life Sciences (SLS) reported Return on Capital Employed of 35.03% for Q1 2026, up 10252.0% year-over-year from N/an in Q1 2025, and up 28.21% quarter-over-quarter from 48.8% in Q4 2025.
SELLAS Life Sciences (SLS) Return on Capital Employed (2012 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 13 years of Return on Capital Employed data on file, last reported at 35.03% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 35.03%, up 10252.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 35.03% (up 10252.0% YoY), and the FY2025 annual result was 67.53%, up 88295.0% from the prior year.
- Return on Capital Employed advanced to 35.03% in Q1 2026 per SLS's latest filing, from 48.8% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 575.3% in Q4 2023 and troughed at 4073.41% in Q1 2024.
- A 5-year average of 558.39% and a median of 300.31% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 368975 bps in 2024, then jumped 393586 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 527.21% in 2022, then jumped by 209 bps to 575.3% in 2023, then sank by 141 bps to 234.15% in 2024, then soared by 79 bps to 48.8% in 2025, then grew by 28 bps to 35.03% in 2026.
- Business Quant data shows SLS's Return on Capital Employed at 35.03% in Q1 2026, 48.8% in Q4 2025, and 74.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | -35.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.03% |
| Dec 31, 2025 | -48.80% |
| Sep 30, 2025 | -74.81% |
| Jun 30, 2025 | -98.38% |
| Mar 31, 2025 | -137.55% |
| Dec 31, 2024 | -234.15% |
| Sep 30, 2024 | -321.33% |
| Jun 30, 2024 | -450.16% |
| Mar 31, 2024 | -4,073.41% |
| Dec 31, 2023 | 575.30% |
| Sep 30, 2023 | -2,459.96% |
| Jun 30, 2023 | -354.55% |
| Mar 31, 2023 | -383.66% |
| Dec 31, 2022 | -527.21% |
| Sep 30, 2022 | -266.56% |
| Jun 30, 2022 | -300.31% |
| Mar 31, 2022 | -301.95% |
| Dec 31, 2021 | -93.23% |
| Sep 30, 2021 | -50.28% |
| Jun 30, 2021 | -40.54% |